ASCOT: a tale of two treatment regimensBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7523.1023 (Published 27 October 2005) Cite this as: BMJ 2005;331:1023
Is ASCOT all it's cracked up to be?
- James A Cave, general practitioner partner (email@example.com)
- Downland Practice, Chieveley, Newbury RG20 8UY
EDITOR—Am I alone in thinking the ASCOT study fails to answer the question it was set toanswer, and moreover raises some more?1 McDougall et al seem sure that it has clearly shown that the new combination of angiotensin converting enzyme (ACE) inhibitor and calcium antagonist is beneficial compared with a β blocker and thiazide.2
Firstly, did the inclusion criteria bias the study against β blockers? Patients with peripheral vascular disease and microalbuminuria were included whereas patients with biochemical abnormalities were not. This looks as if …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial